Nifty’s Pharma index saw a decline after US President Trump announced a 100 percent tariff on branded drugs from October 1. Analysts noted India’s limited exposure to patented drugs in the US market. Most Indian firms focus on generic medicines, which are not affected by the new tariff. Major Indian players also operate manufacturing facilities within the United States.
InvITs industry pushes for easier M&A rules to boost investor interest
India’s InvITs sector, managing ₹7 lakh crore in assets, is urging regulators for simpler M&A rules. Industry leaders want change of control guidelines to match
May 28, 2026